Bringing innovative ADC and SMDC medicines to cancer patients around the world

As a biopharmaceutical company, CanWell Pharma Inc. is committed to accelerating the development and commercialization of first-in-class oncology products for targeted cancers to address highly unmet medical needs.

Founded in 2018, CanWell Pharma is led by several highly accomplished veterans who have an average of 25 years of experience in drug discovery and development in both U.S. and China biopharmaceutical industries. CanWell is dedicated to developing its proprietary first-in-class and best-in-class oncology products to address difficult-to-treat advanced cancers. CanWell is developing a rich R&D pipelines under our technology platforms.

Our Mission

Our mission at CanWell is to develop innovative treatments that harness the power of the immune system to fight cancer. We are devoted to leveraging the latest advances to further explore and develop a variety of innovative therapies. With a focus on collaboration, innovation and patient-centered care, we strive to be at the forefront of cancer therapy and bring new hope to patients and their families.

Antibody Drug Conjugate
ADC program includes StarLinker platform powered Dual-payload/drug, Multi-payload/drug ADCs and high DAR ADCs, as well as immune-stimulating drug conjugates using TLR agonists as payloads.
Read more
Small Molecule Drug Conjugate
Small Molecule Drug Conjugate (SMDC) platform with two clinical drug candidates CAN1012(TLR7 agonists),CAN2109 (ICD inducer) and multiple pre-clinical candidates
Read more

Latest News

10/22/2025

Preliminary Results of CanWell’s CAN1012 (an IFNα-biased TLR7 Agonist) in Combination with Toripalimab was Presented at ESMO 2025

The 2025 European Society for …

Read more
08/08/2025

CanWell will Present Latest ADC Program Updates at 16th World ADC in San Diego, CA (Nov 3-6, 2025)

CanWell Pharma will present it…

Read more

CanWell will Present Clinical Updates on an IFN-α Biased TLR7 Agonist CAN1012 at ESMO 2025 – Annual Meeting (October 17-21, 2025)

CanWell Pharma will present la…

Read more

CanWell will attend ADC & Novel Conjugates Partnering & Investment Summit (September 9-10, 2025)

CanWell Pharma will update com…

Read more